https://www.selleckchem.com/pr....oducts/Sapogenins-gl
3%] vs 20 [37.7%]), headache (57 [27.3%] vs 19 [35.8%]), myalgia (35 [16.7%] vs 10 [18.9%]), and injection-site pain (35 [16.7%] vs 4 [7.5%]). No deaths nor vaccine-related serious adverse events occurred. At Day 29, no anti-SARS-CoV-2 spike serum neutralising antibody and IgG-responses were identified in placebo or the three lower V591 dose-groups; responses were detected with V591 1×10 TCID , although titres were lower than convalescent serum. V591 was generally well tolerated, but immunogenicity was insufficient to warr
Like
Comment
Share
